Latest News for: Boehringer Ingelheim
Edit
First class earns certificates in new MoWest, Boehringer Ingelheim bio-process program
News-Press Now 30 Jun 2026
(News-Press NOW) — The first class of ...
Edit
MoWest and Boehringer Ingelheim Introduce New Bio-Process Certificate Program (Missouri Western State University)
Public Technologies 30 Jun 2026
Edit
HMC, Boehringer Ingelheim sign MoU to advance healthcare innovation in Qatar
Qatar Tribune 29 Jun 2026
Edit
HMC, Boehringer Ingelheim sign MoU to advance healthcare innovation
The Peninsula 29 Jun 2026
Hamad Medical Corporation (HMC) has signed a Memorandum of Understanding (MoU) with Boehringer Ingelheim, one of the world’s leading biopharmaceutical companies, to collaborate on initiatives aimed at ...
Edit
Immunai signs $15M AI drug discovery deal with Boehringer Ingelheim
Ynet 25 Jun 2026
Multi-project collaboration, running ...
Edit
Israeli-founded AI biotech Immunai launches drug-discovery collaboration with Boehringer Ingelheim
The Jerusalem Post 25 Jun 2026
The collaboration will use Immunai’s single-cell AI platform to identify T-cell targets in cancer and autoimmune diseases ....
Edit
Combotope Therapeutics Enters into Collaboration with Boehringer Ingelheim to Advance First-in-Class Tumor-Selective Antibody Therapies for Cancer
PR Newswire 23 Jun 2026
Collaboration spans multiple oncology targets and combines Combotope's SMART-Phage™ discovery platform with Boehringer Ingelheim's research and development expertise ... with Boehringer Ingelheim.
Edit
Boehringer Ingelheim accelerates precision oncology research with initiation of three Phase III trials in hard-to-treat cancers
Nasdaq Globe Newswire 22 Jun 2026
Ingelheim, Germany and Ridgefield, Conn - Boehringer Ingelheim is advancing biomarker-informed approaches and extending ...
Edit
The Daily Record - Dunn
22 Jun 2026
Oxford BioTherapeutics' Third Partnered Programme with Boehringer Ingelheim Enters the Clinic and its First (Obrixtamig) Advances to ...
Edit
Americares Honors Boehringer Ingelheim with Power of Partnership Award (HDMA - Healthcare Distribution Management Association)
Public Technologies 16 Jun 2026
headquarters, with funding provided through the Boehringer Ingelheim Cares Foundation (Boehringer Cares) ... ABOUT BOEHRINGER INGELHEIM Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health.
Edit
Structure of Human adenovirus 7 virus-like particles, a platform for developing nanotherapeutics and studying capsid assembly
PNAS 16 Jun 2026
... .
Edit
Boehringer Ingelheim and Tenity Partner to Launch the Horizon HealthTech Startup Challenge (Tenity Group AG)
Public Technologies 09 Jun 2026
Edit
The Daily Record - Dunn
08 Jun 2026
Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed ...
Company announcement No. 21 / 2026 Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed ....
Edit
Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, ...
Canada Newswire 08 Jun 2026- 1
- 2
- Next page »